CD40 and neoplasm: Strikingly, we also found that higher proportions of circulating or tumor‐infiltrating CD40+ cDC1s and tumor‐infiltrating CD40+ pDCs predicted better clinical outcome (Figure 2b, Supplementary figure 3e, f).